A carregar...
Rituximab does not reset defective early B cell tolerance checkpoints
Type 1 diabetes (T1D) patients show abnormalities in early B cell tolerance checkpoints, resulting in the accumulation of large numbers of autoreactive B cells in their blood. Treatment with rituximab, an anti-CD20 mAb that depletes B cells, has been shown to preserve β cell function in T1D patients...
Na minha lista:
| Publicado no: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Clinical Investigation
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4701568/ https://ncbi.nlm.nih.gov/pubmed/26642366 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI83840 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|